New imaging technique could help doctors predict cancer treatment response
NCT ID NCT01235052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a PET scan using a tracer called FMISO can measure oxygen levels (hypoxia) in head and neck cancers. Sixteen patients received the scan before starting radiotherapy. The goal was to see if the amount of hypoxia seen on the scan could predict how well the cancer responded two years later. The results were not used to change treatment, but to see if this imaging method could be useful in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-FMISO (a radioactive tracer used in PET scans)
What this could lead to
If successful, this could help doctors better predict how head and neck cancers will respond to radiotherapy, potentially guiding more personalized treatment plans.
What could go wrong
This was a very small study (16 people) and only looked at whether the scan could predict outcomes—it did not test a new treatment. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, 33 076, France
-
Hôpital Robert Picqué
Villenave-d'Ornon, 33882, France